HomeTMCI • NASDAQ
add
Treace Medical Concepts Inc
Previous close
$11.27
Day range
$10.73 - $11.51
Year range
$5.27 - $27.70
Market cap
667.67M USD
Avg Volume
348.00K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 62.21M | 25.00% |
Operating expense | 57.45M | 29.84% |
Net income | -6.28M | -42.36% |
Net profit margin | -10.10 | -14.00% |
Earnings per share | -0.10 | -25.00% |
EBITDA | -5.17M | -100.54% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 123.20M | 51.62% |
Total assets | 251.91M | 58.41% |
Total liabilities | 113.97M | 15.71% |
Total equity | 137.94M | — |
Shares outstanding | 61.75M | — |
Price to book | 5.05 | — |
Return on assets | -6.81% | — |
Return on capital | -8.05% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -6.28M | -42.36% |
Cash from operations | 532.00K | 109.93% |
Cash from investing | 5.01M | 107.82% |
Cash from financing | 165.00K | -44.44% |
Net change in cash | 5.70M | 108.26% |
Free cash flow | 1.93M | 127.55% |
About
Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.
In March 2021, Treace announced its intent to launch an initial public offering. Trading on the Nasdaq under the ticker symbol “TMCI”, Treace opened its IPO in April 2021. Wikipedia
Founded
2014
Website
Employees
516
